The role of myosin phosphorylation by myosin light chain kinase (MLCK) in regulating the invasiveness of metastatic cancer cells was investigated using the Dunning rat prostatic adenocarcinoma cell line, Mat Ly Lu, and in vitro invasion assay. Treatment with MLCK inhibitors resulted in marked reduction of invasiveness, which was principally due to impaired cellular motility, whereas the ability to survive and proliferate, to adhere to matrix, and to secrete gelatinases were minimally affected.
Introduction
Invasion of cancer cells through the basement membrane and extracellular matrix is the hallmark of the metastatic process. During invasion, metastatic cancer cells exhibit deregulation of adhesive properties to the neighbouring cells and extracellular matrix, and present motility and secretion of matrix-degrading enzymes. 1 It is possible that these phenomena are caused by modifications of the contractile machineries, which normally power these functions in nonmalignant cells. In this study we determined if myosin II, the conventional myosin, played a role in regulating the invasion process of metastatic cancer cells by inhibiting myosin II function with myosin light chain kinase (MLCK) inhibitors and assessing the effects on the cell invasiveness in vitro.
Myosins II are the major principal contractile proteins of the cells that play important roles in various cellular processes, including controlling of cell shape, cell division, locomotion, contraction and secretion. 2 Myosin II regulates its actin-activated ATPase activity through phosphorylation of its regulatory light chain (MRLC) subunit by a number of protein kinases. Phosphorylation by MLCK on thr 18 and ser 19 has been shown to be critical for the activation of myosin ATPase activity and the contractile functions in smooth and nonmuscle cells. 3, 4 Here, we report that MLCK-catalysed MRLC phosphorylation is also critical for the invasiveness of metastatic cancer cells. Inhibition of invasion was principally caused by impairment of cell motility, while adhesion to matrix and secretion of gelatinases were unaffected. Unlike DNA-damaging drug such as methotrexate, inhibition by MLCK inhibitors occurred at concentrations two to three-fold lower than those required to exert cytotoxic effects, suggesting the potential use of the myosins as targets for prevention and treatment of cancer invasion and metastasis.
Materials and methods
Cell line and cell culture MLL (Mat Ly Lu) prostatic adenocarcinoma cells were kindly provided by Dr Kenneth Pienta (Comprehensive Cancer Center, University of Michigan, Ann Arbor). These cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), l-glutamine and 1 Â antibiotic-antimycotic solution (Life Technologies, Inc., Rockville, MD, USA). The cells were incubated at 371C in a humidified atmosphere containing 5% CO 2 in air.
Drug treatment of cancer cells
Cancer cells were exposed to MLCK inhibitors (ML-7 or ML-9) or methotrexate, and their effects on cancer cell invasion, motility, adhesion and MMP secretion were determined. For MLCK inhibitor treatment, the cells were exposed to ML-7 or ML-9 for 2 h in culture medium, washed twice with PBS before being harvested with trypsin solution and subjected to the various assays. For methotrexate treatment, the cells were exposed to the drug for 24 h before being processed in the same fashion as described for the MLCK inhibitor treatment. Control cells are exposed to the solvents in the absence of drugs.
In vitro invasion assay
Cancer cell invasiveness was determined using transwell chamber (Costar, Cambridge, MA, USA) coated with 0.3 mg/ml matrigel (Collaborative Research Inc., Bedford, MA, USA). Approximately, 1 Â 10 5 cells in culture medium containing FBS were added into the upper and lower compartment of the transwell, respectively, and incubated at 371C in a humidified atmosphere containing 5% CO 2 for 6 h. The filters were fixed with methanol and stained with 0.5% crystal violet in 25% methanol for 1 h, before rinsing with tap water several times. The cells on the upper surface of the filters were gently removed using cotton swabs and the cells that have invaded into the lower surface were counted under a microscope. The numbers of invaded cells in five random Â 10 microscopic fields were counted and expressed as percentage of control. The results shown represented mean7s.e.m. of percentage of invaded cells relative to control from three independent experiments, each carried out in triplicates.
In vitro motility assay
Motility assay was performed in a similar fashion to the invasion assay, except no matrigel coating was applied to the upper surface of the transwell filters. The numbers of invaded cells in five random Â 10 microscopic fields were counted and expressed as percentage of control. The results shown represented mean7s.e.m. of percentage of invaded cells relative to control from three independent experiments, each carried out in triplicates.
Proliferation assay
Aprroximately 3000 cells were cultured in 100 ml RPMI-1640 containing 10% FBS in 96-well plates at 371C in a humidified atmosphere containing 5% CO 2 for 72 h before the numbers of live cells were determined using MTT assay. Briefly, 10 ml of 5 mg/ml MTT solution was added to the culture, incubated for 4 h and the solution was aspirated. The MTT converted into insoluble formazan dye in live cells was then dissolved by addition of 200 ml DMSO before the absorbance was read at 540 nm and expressed as percentage of control (OD 540 of control cells at 72 h in culture was expressed as 100%). The results shown represented mean7s.e.m. of percentage of OD 540 relative to control from three independent experiments, each carried out in triplicates.
Adhesion assay
Each well of a 96-well plate was coated with 0.3 mg/ml matrigel and then incubated with 3% BSA for 1 h at room temperature before addition of cell suspension in culture medium containing 10% FBS. After incubation at 371C for 1 h, the cells in suspension were aspirated, and those bound to matrigel were stained with 5% crystal violet in 25% methanol. After rinsing with tap water, stained cells were counted under a microscope and expressed as percentage of control. The results shown represented mean7s.e.m. of percentage of adherent cells relative to control from three independent experiments, each carried out in triplicates.
Gelatin zymography assay
Cells were starved by culturing in medium without 10% FBS for 24 h before the collection of conditioned medium. The conditioned medium was assayed for gelatinase activity by gelatin zymography assay. Briefly, the conditioned medium was mixed with 2 Â SDS-sample buffer before separation in a 12% SDS-PAGE containing 1 mg/ml gelatin. After electrophoresis at 200 V for 1 h, the gel was washed in a 2.5% Triton X-100 solution twice, 30 min each time. The gel was then incubated in buffer containing 50 mM Tris-HCl, pH 7.5, 10 mM CaCl 2 , 1 mM ZnCl 2 , 1% Triton X-100 and 0.02% NaN 3 for 16-18 h in a 371C water bath, after which the gel was stained with 0.5% Coomassie blue in 30% methanol and 10% acetic acid. After destaining, the clear band of gelatinolytic activity was quantitated using a Biorad GS700 gel scanner.
Statistical analysis
The statistical significance of difference between each group of data was determined by applying Student's two-tailed t-test. A P-value o0.05 was considered significant.
Results
MLL cells exhibited a dose-dependent reduction of invasiveness in response to the drug treatment with similar inhibition profiles for both ML-7 and ML-9 ( Figure 1 ). The IC 50 value for the invasion assay was 5272.0 and 5371.7 mM for ML-7 and ML-9, respectively. A similar inhibition profile was also obtained from the motility assay, showing IC 50 value of 6172.1 and 6472.5 mM for ML-7 and ML-9, respectively. Remarkably, at the highest concentration of drug used in our experiment (75 mM), invasion and motility were almost completely inhibited while the proliferation rate of MLL cells was reduced, at most, by 15%. The MLCK inhibitors had virtually no effect on the ability of MLL Metastatic cancer cell invasion R Tohtong et al cells to survive during the assay period (6 h) (data not shown).
Since the above results showed that MLCK inhibitors significantly reduced invasiveness of the MLL cells by inhibiting cell motility, we further examined if the reduction was due to impaired secretion of the gelatinase activity. Figure 2 illustrates that ML-7 at concentrations up to 50 mM showed no detectable effects on the ability of the MLL cells to secrete the 72 and 74 kDa gelatinases, identified as MMP-2 and pro-MMP-2, respectively. 5 Likewise, the ability of MLL cells to adhere to a matrigel-coated surface was virtually unaffected by the MLCK inhibitor treatment (Figure 3) .
In contrast to the effects produced by the MLCK inhibitors, methotrexate caused severe decrease in cellular invasion and motility concomitant with significant reduction of proliferative ability of the cancer cells (Figure 4) . At the concentrations of methotrexate, which inhibited MLL invasion and motility by 50% (9574.6 and 93.572.5 nM, respectively) and by 95% (1000 nM), proliferation rate of the cancer cells was reduced by 38 and 58%, respectively.
Discussion
The actin-activated ATPase activity and the contractile function of myosin II are principally controlled by the reversible phosphorylation/dephosphorylation reactions of the regulatory subunit of myosin (MRLC).
3,4 MLCKcatalysed phosphorylation of MRLC is essential for the stimulation of myosin ATPase function and is involved in the control of various processes in normal cells such as contraction, motility, secretion, cytokinesis, and cytoskeletal remodeling. 2, 3 Recently, it has been shown that MRLC phosphorylation also plays significant roles in malignant cells by regulating invasiveness and motility 
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The MLL cell, a rat prostatic adenocarcinoma, is highly metastatic in vivo, correlating with its highly invasive behaviour in vitro as demonstrated by the in vitro invasion assay. 11 Here, we show that in vitro invasion of MLL cells was severely inhibited by treatment with the MLCK inhibitors, ML-7 and ML-9, while the ability to survive and proliferate was minimally affected. Both inhibitors exhibited similar dose-dependent inhibition profiles with nearly identical IC 50 values (Figure 1 ), even though the K i values for the pure form of MLCK are about 10-fold different between the two compounds. 12 Although these drugs have inhibitory effects on other protein kinases besides MLCK, 4, [13] [14] [15] [16] it is likely that the reduction of MLL cell invasion is due to the impairment of MLCK, as the affinity of both drugs is at least eightfold higher towards MLCK than other enzymes (viz. K i value of ML-9 for protein kinase A ¼ 32 mM, whereas that for MLCK ¼ 3.8 mM).
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The effects of MLCK inhibitors on the invasiveness paralleled that on the motility of the MLL cells with similar IC 50 values (Figure 1 ), suggesting that impairment of invasion was primarily caused by reduction of cellular motility, consistent with the well-documented role of MRLC phosphorylation in governing motility of nonmuscle cells. However, MLCK inhibitor treatment did not lead to detectable reduction of the ability to adhere to a matrigel surface nor in the ability to secrete matrix-degrading enzymes (Figures 2 and 3) . Lack of effect of ML-7 on cell adhesion to matrigel was in contrast to previous findings in which adhesion of cancer cell to substratum is blocked by ML-7.
6,17 These differences can probably be accounted for by the difference in the sets of adhesion molecules expressed in these cancer cell types, and in the cells' behaviour as determined by the substratum on which they rest. [17] [18] [19] [20] As previous studies have shown that MLCK-catalysed MRLC phosphorylation is involved in a number of secretion processes, [21] [22] [23] we investigated the effects of MLCK inhibitors on the secretion of matrix-degrading enzymes from the MLL cells by gelatin zymography. ML-7 appears to have no detectable effects on the secretion of gelatinase activities from the MLL cells (Figure 3) . Together, these data indicate that the reduction of the invasiveness of the MLL cells caused by MLCK inhibitors was primarily due to the reduction of the ability to locomote, rather than to adhere to the matrix or to secrete matrix-degrading enzymes.
Inhibition of cell motility at nontoxic dose of the drug has been reported for inhibitors of the cytoskeletal proteins, including the microtubule and MLCK. Paclitaxel, a microtubule stabilizer, inhibits motility of paclitaxel-resistant human ovarian carcinoma cells at concentrations about 10 3 -fold lower than those required to show cytotoxic effect. 24 Gillespie et al 6 also reported that MLCK inhibitors, KT-5926 and ML-7, inhibit motility of human glioma cells at nontoxic doses. At KT-5926 concentration that inhibits in vitro motility of cancer cells by 495%, proliferation as determined by [ 3 H]thymidine uptake is reduced only by 28%. Similarly, our data show that ML-7 and ML-9 inhibited in vitro motility and invasion of MLL cells by 490% while cell proliferation was reduced at most by 15% (Figure 1) .
The inhibition properties exhibited by MLCK inhibitors contrast that of DNA-damaging drug as shown in this study by methotrexate, where reduction of motility and invasion paralleled significant reduction of cell proliferation (Figure 4 ). Methotrexate and trimetrexate have been shown to reduce directional migration of glioma cells as determined by tumor spheroid outgrowth at concentrations up to 10-fold higher than those exerting cytotoxic effects in a plating efficiency assay. 25 In addition, neither drug inhibits invasion of glioma spheroids into brain cell aggregates even at concentrations that completely inhibit spheroid growth.
This study demonstrated that in vitro invasion of the MLL cells was severely inhibited by MLCK inhibitors, suggesting that MLCK-catalysed phosphorylation of MRLC plays an important role during invasion of metastatic cancer cells. The inhibition of invasion was primarily caused by reduction of cancer cell motility, rather than by reduction of adhesion to, or degradation of, the matrix through which they penetrate. Remarkably, the concentrations of MLCK inhibitors that suppressed cancer cell invasion showed minimal, if any, effects on the ability of the cells to survive and to proliferate. These data highlight the importance of MLCK-catalysed MRLC phosphorylation in regulating cancer invasiveness, and suggest the potential role of myosin as a target for inhibiting cancer invasion and metastasis. Metastatic cancer cell invasion R Tohtong et al
